SGRY PE Ratio & Valuation,Is SGRY Overvalued

SGRY Relative Valuation

SGRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SGRY is overvalued; if below, it's undervalued.

Historical Valuation

Surgery Partners Inc (SGRY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.58 is considered Undervalued compared with the five-year average of -329.49. The fair price of Surgery Partners Inc (SGRY) is between 20.18 to 36.85 according to relative valuation methord. Compared to the current price of 15.39 USD , Surgery Partners Inc is Undervalued By 23.7%.

Relative Value

Fair Zone

20.18-36.85

Current Price：15.39

23.7%

Undervalued

25.24

13.04

EV/EBITDA

Surgery Partners Inc. (SGRY) has a current EV/EBITDA of 13.04. The 5-year average EV/EBITDA is 18.05. The thresholds are as follows: Strongly Undervalued below 10.90, Undervalued between 10.90 and 14.47, Fairly Valued between 21.62 and 14.47, Overvalued between 21.62 and 25.19, and Strongly Overvalued above 25.19. The current Forward EV/EBITDA of 13.04 falls within the Undervalued range.

16.20

EV/EBIT

Surgery Partners Inc. (SGRY) has a current EV/EBIT of 16.20. The 5-year average EV/EBIT is 19.83. The thresholds are as follows: Strongly Undervalued below 14.83, Undervalued between 14.83 and 17.33, Fairly Valued between 22.33 and 17.33, Overvalued between 22.33 and 24.83, and Strongly Overvalued above 24.83. The current Forward EV/EBIT of 16.20 falls within the Undervalued range.

0.58

Surgery Partners Inc. (SGRY) has a current PS of 0.58. The 5-year average PS is 1.24. The thresholds are as follows: Strongly Undervalued below 0.46, Undervalued between 0.46 and 0.85, Fairly Valued between 1.63 and 0.85, Overvalued between 1.63 and 2.03, and Strongly Overvalued above 2.03. The current Forward PS of 0.58 falls within the Undervalued range.

4.86

P/OCF

Surgery Partners Inc. (SGRY) has a current P/OCF of 4.86. The 5-year average P/OCF is -168.43. The thresholds are as follows: Strongly Undervalued below -1849.44, Undervalued between -1849.44 and -1008.93, Fairly Valued between 672.08 and -1008.93, Overvalued between 672.08 and 1512.59, and Strongly Overvalued above 1512.59. The current Forward P/OCF of 4.86 falls within the Historic Trend Line -Fairly Valued range.

5.56

P/FCF

Surgery Partners Inc. (SGRY) has a current P/FCF of 5.56. The 5-year average P/FCF is 5.81. The thresholds are as follows: Strongly Undervalued below -169.52, Undervalued between -169.52 and -81.86, Fairly Valued between 93.47 and -81.86, Overvalued between 93.47 and 181.14, and Strongly Overvalued above 181.14. The current Forward P/FCF of 5.56 falls within the Historic Trend Line -Fairly Valued range.

Surgery Partners Inc (SGRY) has a current Price-to-Book (P/B) ratio of 1.16. Compared to its 3-year average P/B ratio of 1.85 , the current P/B ratio is approximately -37.26% higher. Relative to its 5-year average P/B ratio of 3.58, the current P/B ratio is about -67.61% higher. Surgery Partners Inc (SGRY) has a Forward Free Cash Flow (FCF) yield of approximately 9.67%. Compared to its 3-year average FCF yield of 4.68%, the current FCF yield is approximately 106.61% lower. Relative to its 5-year average FCF yield of 4.25% , the current FCF yield is about 127.34% lower.

1.16

P/B

Median3y

1.85

Median5y

3.58

9.67

FCF Yield

Median3y

4.68

Median5y

4.25

Competitors Valuation Multiple

The average P/S ratio for SGRY's competitors is 0.33, providing a benchmark for relative valuation. Surgery Partners Inc Corp (SGRY) exhibits a P/S ratio of 0.58, which is 77.46% above the industry average. Given its robust revenue growth of 6.63%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of SGRY decreased by 26.17% over the past 1 year. The primary factor behind the change was an increase in Margin Expansion from 0.83 to 3.08.

The secondary factor is the Revenue Growth, contributed 6.63%to the performance.

Overall, the performance of SGRY in the past 1 year is driven by Margin Expansion. Which is more sustainable.

6.63%

770.40M → 821.50M

Revenue Growth

271.08%

0.83 → 3.08

Margin Expansion

-303.88%

5.66 → -11.53

P/E Change

-26.17%

21.17 → 15.63

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Surgery Partners Inc (SGRY) currently overvalued or undervalued?

What is Surgery Partners Inc (SGRY) fair value?

SGRY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Surgery Partners Inc (SGRY) is between 20.18 to 36.85 according to relative valuation methord.

How does SGRY's valuation metrics compare to the industry average?

What is the current P/B ratio for Surgery Partners Inc (SGRY) as of Dec 15 2025?

As of Dec 15 2025, Surgery Partners Inc (SGRY) has a P/B ratio of 1.16. This indicates that the market values SGRY at 1.16 times its book value.

What is the current FCF Yield for Surgery Partners Inc (SGRY) as of Dec 15 2025?

As of Dec 15 2025, Surgery Partners Inc (SGRY) has a FCF Yield of 9.67%. This means that for every dollar of Surgery Partners Inc’s market capitalization, the company generates 9.67 cents in free cash flow.

What is the current Forward P/E ratio for Surgery Partners Inc (SGRY) as of Dec 15 2025?

As of Dec 15 2025, Surgery Partners Inc (SGRY) has a Forward P/E ratio of 25.24. This means the market is willing to pay $25.24 for every dollar of Surgery Partners Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Surgery Partners Inc (SGRY) as of Dec 15 2025?

As of Dec 15 2025, Surgery Partners Inc (SGRY) has a Forward P/S ratio of 0.58. This means the market is valuing SGRY at $0.58 for every dollar of expected revenue over the next 12 months.

SGRY Valuation